Overstated earnings, combined with its expensive valuation, make this stock more likely to miss earnings expectations in the short-term and underperform the market in the long-term.
Investment Analyst Kyle Guske II sat down with Chuck Jaffe of Money Life to talk about our Danger Zone pick this week: Earnings Distortion Scorecard Reveals Another Stock to Avoid.
We joined Benzinga’s PreMarket Prep on November 7 to discuss the HBS & MIT Sloan paper, its takeaways, and how you can use our data featured in the paper to pick better stocks.
Investment Analyst Sam McBride sat down with Chuck Jaffe of Money Life to talk about our Danger Zone pick this week: Earnings Distortions Make This Stock a Sell.
Our model portfolios offer clients multiple strategies to outperform in good and bad markets. See the performance of these model portfolios through 3Q19.
We joined TDA Network’s Morning Trade Live on Friday, November 1 to provide insights into Earnings Distortion for companies in the S&P 500, especially AbbVie (ABBV).
Understated earnings and cheap valuation give this company a higher chance of beating earnings in the short-term and outperforming the market in the long-term.